BioSpace News Archive

Tarveda Therapeutics®, Inc., today announced that the company will present results from the Phase 1 portion of a Phase 1/2a study of PEN-866 in patients with advanced solid malignancies at the European Society for Medical Oncology (ESMO) Congress 2019,

Ryan Corcoran is a world leader in oncogenic signaling pathways

ReSolve is an observational study run by the FSHD Clinical Trial Research Network, a network of medical centers across the U.S. and Europe that aims to validate new clinical outcome assessments and refine trial planning strategies in FSHD.

Fitzmaurice Hand Institute and Endotech Surgery Center in Scottsdale, AZ has achieved dual-accreditations as a Center of Excellence in Minimally Invasive Hand Surgery (COEMIHS) and Minimally Invasive Surgery (COEMIS) by Surgical Review Corporation.

These patents are also the subject of a separate patent infringement action Abiomed filed against Thoratec

Lee Savio Beers, M.D., FAAP, Medical Director of Community Health and Advocacy at the Child Health Advocacy Institute (CHAI) at Children’s National Hospital, was elected by her peers to become president-elect of the American Academy of Pediatrics (AAP) beginning Jan. 1, 2020.

Centene Corporation (NYSE: CNC) today issued a reminder that it will release its 2019 third quarter financial results at approximately 6 a.m. (Eastern Time) on Tuesday, October 22, 2019, and host a conference call afterwards at approximately 8:30 a.m. (Eastern Time) to review the results.

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that the Company will be presenting updated data from the ongoing Phase 1 dose-escalation trials of AB928, a potential best-in-class dual antagonist of adenosine receptors A2aR and A2bR, in a poster display session at the 2019 European Society for Medical Oncology (ESMO) Annual Meeting

New England ABA, Inc will operate as a subsidiary of The Stepping Stones Group and continue to do business under its current name.

Entered into a license agreement to promote and distribute the second brand TECERIS for the anticancer agent eribulin mesylate (eribulin) in India.